SOLIGENIX INC (SNGX) Stock Price & Overview
NASDAQ:SNGX • US8342236044
The current stock price of SNGX is 1.23 USD. Today SNGX is down by 0%. In the past month the price increased by 9.82%. In the past year, price decreased by -46.52%.
SNGX Key Statistics
- Market Cap
- 12.411M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.60
- Dividend Yield
- N/A
SNGX Stock Performance
SNGX Stock Chart
SNGX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to SNGX. When comparing the yearly performance of all stocks, SNGX is a bad performer in the overall market: 91.18% of all stocks are doing better.
SNGX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SNGX. While SNGX seems to be doing ok healthwise, there are quite some concerns on its profitability.
SNGX Earnings
SNGX Forecast & Estimates
7 analysts have analysed SNGX and the average price target is 17.85 USD. This implies a price increase of 1351.22% is expected in the next year compared to the current price of 1.23.
For the next year, analysts expect an EPS growth of 64.11% and a revenue growth -100% for SNGX
SNGX Groups
Sector & Classification
SNGX Financial Highlights
Over the last trailing twelve months SNGX reported a non-GAAP Earnings per Share(EPS) of -3.6. The EPS increased by 58.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -101.45% | ||
| ROE | -150.79% | ||
| Debt/Equity | 0 |
SNGX Ownership
SNGX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.34 | 401.392B | ||
| AMGN | AMGEN INC | 16.55 | 202.383B | ||
| GILD | GILEAD SCIENCES INC | 16.52 | 184.425B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.4 | 126.804B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.57 | 81.619B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.95 | 42.754B | ||
| INSM | INSMED INC | N/A | 31.007B | ||
| NTRA | NATERA INC | N/A | 28.197B | ||
| BIIB | BIOGEN INC | 11.85 | 27.651B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.24 | 23.485B | ||
| MRNA | MODERNA INC | N/A | 21.714B | ||
| EXAS | EXACT SCIENCES CORP | 340.18 | 19.732B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.591B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SNGX
Company Profile
Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. The company is headquartered in Princeton, New Jersey and currently employs 14 full-time employees. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).
Company Info
IPO: 1994-04-04
SOLIGENIX INC
29 Emmons Drive, Suite B-10
Princeton NEW JERSEY 08540 US
CEO: Christopher J. Schaber
Employees: 14
Phone: 16095388200
SOLIGENIX INC / SNGX FAQ
Can you describe the business of SOLIGENIX INC?
Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. The company is headquartered in Princeton, New Jersey and currently employs 14 full-time employees. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).
What is the stock price of SOLIGENIX INC today?
The current stock price of SNGX is 1.23 USD.
Does SNGX stock pay dividends?
SNGX does not pay a dividend.
How is the ChartMill rating for SOLIGENIX INC?
SNGX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Would investing in SOLIGENIX INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SNGX.
What is the expected growth for SNGX stock?
The Revenue of SOLIGENIX INC (SNGX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the employee count for SNGX stock?
SOLIGENIX INC (SNGX) currently has 14 employees.